Literature DB >> 7888039

Analysis of the spontaneous T cell response to insulin in NOD mice.

D R Wegmann1, R G Gill, M Norbury-Glaser, N Schloot, D Daniel.   

Abstract

Insulin-specific T cells have been found to be present in high frequency among nominally islet-cell-specific T cells in the islet infiltrates that accumulate in NOD mice. In a previous report in which clones obtained from 7- and 12-week-old mice were examined, we identified a 15-residue peptide of the B chain as the dominent epitope for this response. Despite the fact that the response to insulin appears to be directed toward this single peptide, diverse TCR V beta usage was observed. That insulin-specific T cells contribute to beta cell damage is suggested by the fact that all clones tested could mediate beta cell destruction upon adoptive transfer. In the present report we extend this examination of insulin-specific T cells to lines and clones established from mice ranging in age from 4-12 weeks. These clones were found to be very similar to those from 7- and 12-week-old mice. The response was directed to the same peptide and most were found to produce IFN gamma, but none produced IL-4.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888039     DOI: 10.1006/jaut.1994.1066

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  35 in total

1.  A pancreatic beta-cell-specific homolog of glucose-6-phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes.

Authors:  John C Hutton; George S Eisenbarth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-14       Impact factor: 11.205

Review 2.  The non obese diabetic (NOD) mouse: a unique model for understanding the interaction between genetics and T cell responses.

Authors:  William M Ridgway
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

3.  Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice.

Authors:  D G Karounos; J S Bryson; D A Cohen
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development.

Authors:  Alexandra I Ziegler; Melanie A Le Page; Mhairi J Maxwell; Jessica Stolp; Haoyao Guo; Abhirup Jayasimhan; Margaret L Hibbs; Pere Santamaria; Jacques F Miller; Magdalena Plebanski; Pablo A Silveira; Robyn M Slattery
Journal:  Diabetologia       Date:  2013-09-08       Impact factor: 10.122

Review 5.  Antigen-specific therapy for autoimmune disease: prospects for the prevention of insulin-dependent diabetes.

Authors:  L C Harrison
Journal:  Mol Med       Date:  1995-11       Impact factor: 6.354

6.  Prevention of type I diabetes transfer by glutamic acid decarboxylase 65 peptide 206-220-specific T cells.

Authors:  Seon-Kyeong Kim; Kristin V Tarbell; Maija Sanna; Mary Vadeboncoeur; Tibor Warganich; Mark Lee; Mark Davis; Hugh O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

7.  No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.

Authors:  Markus Walter; Areti Philotheou; François Bonnici; Anette-G Ziegler; Roland Jimenez
Journal:  Diabetes Care       Date:  2009-08-18       Impact factor: 19.112

8.  Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice.

Authors:  M G von Herrath; T Dyrberg; M B Oldstone
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

9.  Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23).

Authors:  D Daniel; D R Wegmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

10.  T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event.

Authors:  Greig P Lennon; Maria Bettini; Amanda R Burton; Erica Vincent; Paula Y Arnold; Pere Santamaria; Dario A A Vignali
Journal:  Immunity       Date:  2009-10-08       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.